**Health Disparities and Tobacco**

U.S. Tobacco Control Policies to Reduce Health Disparities*

PAR-18-675 (R01 Clinical Trial Optional);
PAR-18-674 (R21 Clinical Trial Optional)

**Focus:** Innovative tobacco control policies to reduce disparities in health outcomes related to tobacco use.

---

**Tobacco Use and HIV in Low- and Middle-Income Countries**

**Focus:** Development and evaluation of tobacco cessation interventions tailored to HIV-positive populations in low-resource settings.

---

**Improving Smoking Cessation Interventions among People Living with HIV**

**Focus:** Optimizing smoking cessation treatment among people living with HIV in the United States.

---

**Electronic Nicotine Delivery Systems (ENDS) and Vaping**


PAR-18-847 (R01 Clinical Trial Optional)

**Focus:** Determinants of risk and protective factors related to the trajectories of ENDS use patterns, how ENDS use may influence intentions to quit and cessation of tobacco products, intervention and policy approaches to address ENDS use among vulnerable populations, and potential contributions to cancer risk from ENDS use.

---

**Data Analysis**

Maximizing the Scientific Value of Existing Biospecimen Collections

RFA-OD-19-021 (R21 Clinical Trial Not Allowed)

**Focus:** Exploratory research relevant to the mission of FDA’s Center for Tobacco Products using existing (publicly available) biospecimens.

---

**Secondary Analyses of Existing Datasets of Tobacco Use and Health**

RFA-OD-19-022 (R21 Clinical Trial Not Allowed)

**Focus:** Innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies in areas relevant to FDA’s Center for Tobacco Products.

---

**Tobacco Control Policy and Regulatory Research**

Notice to Study the Population Impact(s) of the Court-Ordered, Tobacco-Related Corrective Statements

PAR-19-064 (R21 Clinical Trial Optional)

**Focus:** Corrective statements implemented as part of the Department of Justice’s racketeering case, “United States v. Philip Morris USA.”

---

**Public Policy Effects on Alcohol-, Marijuana-, and Other Substance-Related Behaviors and Outcomes**

PA-17-135 (R01 Clinical Trial Not Allowed);
PA-17-132 (R21 Clinical Trial Not Allowed);
PA-17-134 (R03 Clinical Trial Not Allowed)

**Focus:** How public policy may serve as a tool for improving public health and welfare through its effects on behaviors and outcomes pertaining to alcohol, marijuana, and other drugs.

---

**Tobacco Regulatory Science**

RFA-OD-19-028 (R01 Clinical Trial Optional)

**Focus:** Biomedical and behavioral research to inform regulation of tobacco products to protect public health. Projects must address the priorities related to the regulatory authority of FDA’s Center for Tobacco Products.

---

https://cancercontrol.cancer.gov/brp/funding/funding-opportunities.html#tcrb

*NCI-led FOAs*
Data Analysis, continued
Multi-Site Pilot & Feasibility Studies for System-Level Implementation of Substance Use Prevention and Treatment Services
PAR-18-223 (R34 Clinical Trial Optional)
Focus: Strategies for systems-level change to promote broad use of evidence-based practices for the prevention and/or treatment of substance use disorders, including tobacco cessation services.

Specific Interest Funding Opportunities
FOA opportunities for investigator-driven research.
Notice of Special Interest (NOSI): Dissemination and Implementation Science for Cancer Prevention and Control in Low Resource Environments*
NOT-CA-20-025
Focus: Implementation research related to cancer prevention and control in low- and middle-income countries and in low resource settings.

National Institutes of Health (NIH) Research Project Grant
PA-19-056 (Parent R01 Clinical Trial Not Allowed)
Focus: A discrete, specified, circumscribed project in areas representing the specific interests and competencies of the investigator(s).

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control*
PAR-19-309 (R21 Clinical Trial Optional)
Focus: New research testing new theories and conceptual frameworks; developing and evaluating novel strategies to improve cancer-related health behaviors; investigating multi-level and multi-behavioral approaches; and utilizing innovative research designs, methodologies, and technologies.

Integrative Research on Polysubstance Abuse and Addiction
PAR-18-084 (R21/R33 Clinical Trial Optional)
Focus: How neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; Integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies.

Career Development Awards
FOAs that support individual and institutional research training opportunities focused on tobacco research.

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research
RFA-OD-18-005 (K01 Independent Clinical Trial Not Allowed); RFA-OD-18-006 (K01 Independent Clinical Trial Required)

Pathway to Independence Award in Tobacco Regulatory Research
RFA-OD-18-007 (K99/R00 Independent Clinical Trial Not Allowed); RFA-OD-18-008 (K99/R00 Independent Clinical Trial Required)

Modular R01s
Modular R01s in Cancer Control and Population Sciences*
PAR-18-869 (R01 Clinical Trial Optional)
Modular R01s are available for projects that require a shorter timeline and reduced budget compared to other grant-funded projects. TCRB is most interested in behavioral research topics related to tobacco control, including but not limited to studies that:

- Investigate patterns, trends, and determinants of tobacco use behaviors
- Evaluate methods, measurements and/or modeling of tobacco-related behaviors to better understand the effects of diverse tobacco control and tobacco use treatment interventions
- Examine cancer-related behaviors and biobehavioral risk factors
- Develop and/or evaluate multi-level interventions that address combinations of biological, psychological, behavioral, social, environmental, and/or policy targets
- Use conventional, social, and mobile media for cancer control and prevention observational studies and interventions

*NCI-led FOAs
Note: Not a comprehensive list of all tobacco-related FOAs; please consult the NIH Guide for all available funding opportunities.